Equities

ANGN

US03476J1079

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
4.79 ^USD	+4.81%		+5.51%	-52.10%

2023	Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	CI
2023	Angion Biomedia to Implement 10-for-1 Reverse Split	MT

Angion Biomedica Corp. Auditor Raises 'Going Concern' Doubt

January 14, 2021

Angion Biomedica Corp. filed its Annual on Jan 15, 2021 for the period ending Dec 31, 2019. In this report its auditor, Moss Adams LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about ANGN BIOM

Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	30/08/23	CI
Angion Biomedia to Implement 10-for-1 Reverse Split	01/06/23	MT
Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from NASDAQ Composite Index	01/06/23	CI
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	31/05/23	CI
Angion Biomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Sector Update: Health Care Stocks Finishing Near Intra-Day Lows	17/01/23	MT
Sector Update: Health Care Stocks Sputtering in Tuesday Trading	17/01/23	MT
Top Midday Decliners	17/01/23	MT
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures	17/01/23	MT
Top Premarket Decliners	17/01/23	MT
Angion Biomedica Agrees to Merge With Elicio Therapeutics	17/01/23	MT
Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others for $49 million in a reverse merger transaction.	16/01/23	CI
Angion Biomedica Gets Non-Compliance Notice From Nasdaq	22/12/22	MT
Angion Biomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Angion Biomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Revenue $653,000	15/08/22	MT
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Loss $-0.30	15/08/22	MT
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value	26/07/22	CI
Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022	25/07/22	CI
Angion Biomedica to Explore Strategic Alternatives to Boost Shareholder Value	25/07/22	MT
HC Wainwright Downgrades Angion Biomedica to Neutral From Buy	18/07/22	MT
Sector Update: Health Care Stocks Swoon Late, Closing Lower	30/06/22	MT
Top Midday Decliners	30/06/22	MT
Sector Update: Health Care Stocks Little Changed on Thursday	30/06/22	MT
Sector Update: Health Care	30/06/22	MT

Chart ANGN BIOM

Duration

Period

More charts

Company Profile

Angion Biomedica Corp. is a clinical-stage company. The Company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company's product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.

Sector

More about the company

Income Statement Evolution

More financial data